vimarsana.com
Home
Live Updates
Antengene To Present Latest Results from TORCH-2 Study of AT
Antengene To Present Latest Results from TORCH-2 Study of AT
Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023
/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...
Related Keywords
Beijing ,
China ,
Australia ,
Singapore ,
South Korea ,
Chicago ,
Illinois ,
United States ,
Mccormick Place ,
Shanghai ,
Hong Kong ,
Taiwan ,
American ,
Peter Qian ,
Asia Pacific ,
Hong Kong Stock Exchange ,
Prnewswire Antengene Corporation Limited ,
Company Annual ,
Eastern Cooperative Oncology Group ,
Antengene Corporation Limited ,
American Society For Clinical Oncology Annual Meeting ,
Antengene Corporation ,
Mccormick Place Convention Center ,
Corporation Limited ,
Clinical Oncology Annual Meeting ,
Poster Discussions ,
Poster Discussion ,
Family Zhang ,
Chief Medical ,
Developmental Therapeutics ,
Discussion Session Date ,
Central Time ,
Beijing Time ,
Cervical Cancer Cohort ,
Nasopharyngeal Carcinoma ,
Evaluation Did Not Identify ,
Dose Limiting Toxicity ,
Maximum Tolerated Dose ,
Dose Escalation Phase ,
Patients Beyond ,
Mainland China ,
Taiwan China ,
Annual Report ,
Hong Kong Stock ,